1. Home
  2. ENTA vs RFI Comparison

ENTA vs RFI Comparison

Compare ENTA & RFI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Enanta Pharmaceuticals Inc.

ENTA

Enanta Pharmaceuticals Inc.

HOLD

Current Price

$13.30

Market Cap

378.0M

Sector

Health Care

ML Signal

HOLD

Logo Cohen & Steers Total Return Realty Fund Inc.

RFI

Cohen & Steers Total Return Realty Fund Inc.

HOLD

Current Price

$11.45

Market Cap

310.3M

Sector

Finance

ML Signal

HOLD

Company Overview

Basic Information
Metric
ENTA
RFI
Founded
1995
1992
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Investment Managers
Sector
Health Care
Finance
Exchange
Nasdaq
Nasdaq
Market Cap
378.0M
310.3M
IPO Year
2012
N/A

Fundamental Metrics

Financial Performance
Metric
ENTA
RFI
Price
$13.30
$11.45
Analyst Decision
Strong Buy
Analyst Count
5
0
Target Price
$20.40
N/A
AVG Volume (30 Days)
156.5K
102.1K
Earning Date
05-11-2026
01-01-0001
Dividend Yield
N/A
8.25%
EPS Growth
29.93
N/A
EPS
N/A
N/A
Revenue
$102,814,000.00
N/A
Revenue This Year
$7.76
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
16.48
N/A
52 Week Low
$7.05
$10.78
52 Week High
$17.15
$12.17

Technical Indicators

Market Signals
Indicator
ENTA
RFI
Relative Strength Index (RSI) 51.08 48.17
Support Level $12.95 $11.33
Resistance Level $13.98 $11.72
Average True Range (ATR) 0.58 0.14
MACD 0.01 -0.02
Stochastic Oscillator 61.40 29.56

Price Performance

Historical Comparison
ENTA
RFI

About ENTA Enanta Pharmaceuticals Inc.

Enanta Pharmaceuticals Inc is a biotechnology company that uses a chemistry-based drug discovery approach to develop small-molecule candidates for virology and immunology applications. It focuses on Virology and Immunology. Its active development programs in virology are focused on respiratory syncytial virus, or RSV, and SARS-CoV-2, and Hepatitis B virus. In immunology, the company is engaged in designing and developing potent and selective, oral small molecule inhibitors for the treatment of type 2 inflammatory disease. The company has collaborated with AbbVie, which markets its protease inhibitor paritaprevir, with additional inhibitors in development. The company generates the majority revenue in the form of royalty revenue.

About RFI Cohen & Steers Total Return Realty Fund Inc.

Cohen & Steers Total Return Realty Fund Inc is a diversified closed-end management investment company. Its investment objective is to achieve a high total return through investment in real estate securities. The Fund invests majority of its total assets in the equity securities of real estate companies under normal circumstances, which includes common shares, REITs, rights or warrants, convertible securities, and preferred shares.

Share on Social Networks: